サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1428058

ワクチン受託製造の世界市場レポート 2024

Vaccine Contract Manufacturing Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
ワクチン受託製造の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

ワクチン受託製造の市場規模は、今後数年間で急速に成長すると予想されています。 2028年には10.1%の年間複合成長率（CAGR）で53億2,000万米ドルに成長すると予想されます。予測期間で予想される成長は、パンデミックへの備えの重視の高まり、医薬品製造におけるアウトソーシングの増加、バイオ医薬品企業の拡大、ワクチン開発のスケジュールの加速、およびワクチンの利用しやすさの向上を目的とした世界の取り組みに起因すると考えられます。予測期間中に予想される顕著な動向には、製造におけるシングルユース技術の統合、ワクチン開発への個別化医療アプローチの増加、mRNAおよびウイルスベクターワクチンの開発、連続製造プロセスの採用、充填剤の拡大などが含まれます。

ワクチン接種を促進する取り組みの増加が予想され、今後ワクチン受託製造市場の成長を促進すると予想されます。ワクチン接種は、免疫システムを強化し、体の防御を強化することにより、伝染病から身を守るための簡単で安全かつ効果的な方法として機能します。ワクチン接種を支持する取り組みが増加するにつれ、ワクチン受託製造をサポートするためのさまざまなワクチン製造プロセスの進歩と強化が期待されます。例示的な例は、米国保健福祉省が2022年11月に発表した、特に疎外されたコミュニティ向けの新型COVID-19感染症ワクチンの入手可能性を高めるため、HRSA（保健資源サービス局）が支援する医療施設に対して3億5,000万米ドルの新たな取り組みを発表したことです。したがって、ワクチン接種をサポートする取り組みの急増は、ワクチン受託製造市場の成長の促進剤となります。

世界の感染症の増加は、ワクチン受託製造市場の拡大に寄与すると予想されます。細菌、ウイルス、真菌、寄生虫などの微生物によって引き起こされる感染症は、さらなる蔓延を抑制するために、流行中に緊急のワクチン開発を必要とします。受託製造業者は、これらの流行に対処するためにワクチン生産を迅速に拡大する上で重要な役割を果たします。たとえば、英国では、2022年12月9日までの週の終わりまでに、特定の年齢層および学年の感染率が増加しました。感染率が上昇するにつれてワクチンの緊急性が明らかになり、感染症に効果的に対応するためのワクチン受託製造の必要性が高まっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界のワクチン受託製造市場促進要因と制約要因
    • 市場の促進要因
    • 市場の抑制要因
  • 世界のワクチン受託製造市場規模実績と成長率、2018～2023年
  • 世界のワクチン受託製造市場規模と成長予測、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のワクチン受託製造市場、サービスタイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 充填
  • バルク
  • 世界のワクチン受託製造市場、ワクチンタイプ別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 不活化ワクチン
  • 弱毒化生ワクチン
  • RNA（リボ核酸）ワクチン
  • サブユニットワクチン
  • トキソイドベースのワクチン
  • 世界のワクチン受託製造市場、プロセス別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • ダウンストリーム
  • アップストリーム
  • 世界のワクチン受託製造市場、事業規模別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 前臨床
  • 臨床
  • 商用
  • 世界のワクチン受託製造市場、エンドユース別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 人間への使用
  • 獣医

第7章 地域および国の分析

  • 世界のワクチン受託製造市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界のワクチン受託製造市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • ワクチン受託製造市場の競合情勢
  • ワクチン受託製造市場企業プロファイル
    • Pfizer Inc
    • Johnson &Johnson
    • AbbVie Inc.
    • Sanofi
    • GlaxoSmithKline

第31章 その他の大手および革新的な企業

  • Merck KGaA
  • Fujifilm Holdings Corporation
  • Moderna
  • BioNTech
  • GSK Vaccines
  • AstraZeneca PLC
  • Ajinomoto Co. Inc.
  • Icon plc
  • Lonza Group AG
  • Cytiva
  • Catalent Inc.
  • Charles River Laboratories International Inc.
  • Serum Institute of India Pvt. Ltd
  • Samsung Biologics
  • WuXi Biologics

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13902

Vaccine contract manufacturing involves an arrangement where outside producers are engaged to create vaccines, overseeing the production, packing, and labeling of vaccines based on the specifications and demands of the contracting business or organization. The primary benefit of vaccine contract manufacturing is the simplification of production, resulting in cost savings and fewer operational challenges.

The main types of services involved in vaccine contract manufacturing include fill-finish and bulk products. Fill-finish specifically pertains to the filling and finishing stages of the vaccine manufacturing process. In the pharmaceutical industry, finishing involves the sterilization and standardization of vaccine components into containers, while filling refers to adding them to containers and sealing them properly. The vaccines produced through this process include inactivated vaccines, live-attenuated vaccines, RNA (ribonucleic acid) vaccines, subunit vaccines, and toxoid-based vaccines. These vaccines are prepared through downstream and upstream processes on preclinical, clinical, and commercial scales of operation, catering to both human use and veterinary end-users.

The vaccine contract manufacturing research report is one of a series of new reports from The Business Research Company that provides vaccine contract manufacturing market statistics, including the vaccine contract manufacturing industry's global market size, regional shares, competitors with vaccine contract manufacturing market share, detailed vaccine contract manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the vaccine contract manufacturing industry. This vaccine contract manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The vaccine contract manufacturing market size has grown strongly in recent years. It will grow from $3.3 billion in 2023 to $3.62 billion in 2024 at a compound annual growth rate (CAGR) of 9.9%. The expansion observed in the historical period can be attributed to limitations in traditional vaccine manufacturing, increased demand driven by global disease outbreaks, regulatory support for contract manufacturing, the growing complexity of vaccine production, and a surge in vaccine research and development.

The vaccine contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $5.32 billion in 2028 at a compound annual growth rate (CAGR) of 10.1%. The anticipated growth in the forecast period can be attributed to an increased emphasis on pandemic preparedness, a rise in outsourcing within pharmaceutical manufacturing, the expansion of biopharmaceutical companies, accelerated timelines for vaccine development, and global initiatives aimed at improving vaccine accessibility. Prominent trends expected during the forecast period include the integration of single-use technologies in manufacturing, an increase in personalized medicine approaches to vaccine development, the development of mRNA and viral vector vaccines, the adoption of continuous manufacturing processes, and the expansion of fill-finish services.

The anticipated rise in initiatives promoting vaccinations is set to drive the growth of the vaccine contract manufacturing market in the future. Vaccination serves as an easy, safe, and effective method to defend against contagious diseases by enhancing the immune system and fortifying the body's defenses. The advancement and enhancement of various vaccine manufacturing processes to support vaccine contract manufacturing are expected with increasing initiatives favoring vaccinations. An illustrative example is the U.S. Department of Health and Human Services' announcement in November 2022 of a new $350 million initiative for HRSA (Health Resources and Services Administration)-supported health facilities to enhance COVID-19 vaccine availability, particularly for marginalized communities. Thus, the surge in initiatives supporting vaccinations is a catalyst for the growth of the vaccine contract manufacturing market.

The global rise in infectious diseases is anticipated to contribute to the expansion of the vaccine contract manufacturing market. Infectious diseases caused by microorganisms, such as bacteria, viruses, fungi, or parasites, necessitate urgent vaccine development during outbreaks to curb their further spread. Contract manufacturers play a crucial role in rapidly scaling up vaccine production to address these outbreaks. For example, in England, by the end of the week ending December 9, 2022, infection rates increased for specific age groups and school years. The urgency for vaccines is evident as the infection rate rises, driving the need for vaccine contract manufacturing to respond effectively to infectious diseases.

A notable trend gaining traction in the vaccine contract manufacturing market is strategic partnerships. Leading companies are forming partnerships with entities operating in the vaccine contract manufacturing sector to solidify their market positions. An instance is the collaboration between Vaxxas, an Australia-based biotechnology company specializing in needle-free vaccination technology, and the Coalition for Epidemic Preparedness Innovations, with a focus on developing new vaccines and advancing Vaxxas' needle-free vaccine patch delivery technology. Additionally, the partnership between Novartis AG, Pfizer Inc., and BioNTech SE demonstrates collaborative efforts to provide manufacturing capacity for the Pfizer-BioNTech COVID-19 vaccine, illustrating the significance of strategic partnerships in the vaccine contract manufacturing market.

Major companies in the vaccine contract manufacturing market are directing their efforts toward establishing production sites dedicated to vaccine contract manufacturing. This entails creating facilities exclusively for the manufacturing and production of vaccines on a contractual basis. WuXi Vaccines, a China-based contract development and manufacturing organization (CDMO), expanded its capabilities with the opening of its first standalone vaccine CDMO site in Suzhou, China, in September 2023. This expansion enhances WuXi Vaccines' capacity to contribute to vaccine development and manufacturing, reinforcing its pivotal role in advancing global healthcare solutions.

In November 2021, CJ CheilJedang Corporation, a South Korea-based conglomerate, acquired Batavia Biosciences for $226 million. This strategic acquisition aimed to expand CJ CheilJedang Corporation's bio business portfolio and foster synergies with other wellness-related companies in the long term. Batavia Biosciences, based in the Netherlands, is a science-based contract development and manufacturing organization (CDMO) specializing in viral vectors and vaccines, providing services from process development to clinical and commercial manufacturing.

Major companies operating in the vaccine contract manufacturing market report are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Sanofi, GlaxoSmithKline, Merck KGaA, Fujifilm Holdings Corporation, Moderna, BioNTech, GSK Vaccines, AstraZeneca PLC, Ajinomoto Co. Inc., Icon PLC, Lonza Group AG, Cytiva, Catalent Inc., Charles River Laboratories International Inc., Serum Institute of India Pvt. Ltd., Samsung Biologics, WuXi Biologics, Novavax, Sinovac Biotech, Emergent BioSolutions Inc., Albany Molecular Research Inc., Soligenix Inc., Bio Farma, Curia Global Inc., Hualan Biological Engineering, BioMARC, Bavarian Nordic A/S, AGC Biologics, IDT Biologika GmbH, Bharat Biotech, Goodwin Biotechnology Inc., Biofabri S.L

North America was the largest region in the vaccine contract manufacturing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the vaccine contract manufacturing market report forecast period. The regions covered in the vaccine contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the vaccine contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vaccine contract manufacturing market consists of revenues earned by entities by providing services such as analytical, quality control studies, cell or virus banking, and cold chain services. The market value includes the value of related goods sold by the service provider or included within the service offering. The vaccine contract manufacturing market also includes sales of synthetic vaccines and DNA (deoxyribonucleic acid) vaccines, which are used in providing vaccine contract manufacturing services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vaccine Contract Manufacturing Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vaccine contract manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vaccine contract manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vaccine contract manufacturing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Service Type: Fill-Finish; Bulk Product
  • 2) By Vaccine Type: Inactivated Vaccines; Live-Attenuated Vaccines; RNA (Ribonucleic Acid) Vaccines; Subunit Vaccines; Toxoid-Based Vaccines
  • 3) By Process: Downstream; Upstream
  • 4) By Scale Of Operation: Preclinical; Clinical; Commercial
  • 5) By End-Use: Human Use; Veterinary
  • Companies Mentioned: Pfizer Inc; Johnson & Johnson; AbbVie Inc.; Sanofi; GlaxoSmithKline
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Vaccine Contract Manufacturing Market Characteristics

3. Vaccine Contract Manufacturing Market Trends And Strategies

4. Vaccine Contract Manufacturing Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Vaccine Contract Manufacturing Market Size and Growth

  • 5.1. Global Vaccine Contract Manufacturing Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Vaccine Contract Manufacturing Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Vaccine Contract Manufacturing Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Vaccine Contract Manufacturing Market Segmentation

  • 6.1. Global Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Fill-Finish
  • Bulk Product
  • 6.2. Global Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Inactivated Vaccines
  • Live-Attenuated Vaccines
  • RNA (Ribonucleic Acid) Vaccines
  • Subunit Vaccines
  • Toxoid-Based Vaccines
  • 6.3. Global Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Downstream
  • Upstream
  • 6.4. Global Vaccine Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Preclinical
  • Clinical
  • Commercial
  • 6.5. Global Vaccine Contract Manufacturing Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Human Use
  • Veterinary

7. Vaccine Contract Manufacturing Market Regional And Country Analysis

  • 7.1. Global Vaccine Contract Manufacturing Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Vaccine Contract Manufacturing Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Vaccine Contract Manufacturing Market

  • 8.1. Asia-Pacific Vaccine Contract Manufacturing Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Vaccine Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Vaccine Contract Manufacturing Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Vaccine Contract Manufacturing Market

  • 9.1. China Vaccine Contract Manufacturing Market Overview
  • 9.2. China Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Vaccine Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Vaccine Contract Manufacturing Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Vaccine Contract Manufacturing Market

  • 10.1. India Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Vaccine Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Vaccine Contract Manufacturing Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Vaccine Contract Manufacturing Market

  • 11.1. Japan Vaccine Contract Manufacturing Market Overview
  • 11.2. Japan Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Vaccine Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Vaccine Contract Manufacturing Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Vaccine Contract Manufacturing Market

  • 12.1. Australia Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Vaccine Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Vaccine Contract Manufacturing Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Vaccine Contract Manufacturing Market

  • 13.1. Indonesia Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Vaccine Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Vaccine Contract Manufacturing Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Vaccine Contract Manufacturing Market

  • 14.1. South Korea Vaccine Contract Manufacturing Market Overview
  • 14.2. South Korea Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Vaccine Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Vaccine Contract Manufacturing Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Vaccine Contract Manufacturing Market

  • 15.1. Western Europe Vaccine Contract Manufacturing Market Overview
  • 15.2. Western Europe Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Vaccine Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Vaccine Contract Manufacturing Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Vaccine Contract Manufacturing Market

  • 16.1. UK Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Vaccine Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Vaccine Contract Manufacturing Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Vaccine Contract Manufacturing Market

  • 17.1. Germany Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Vaccine Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Vaccine Contract Manufacturing Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Vaccine Contract Manufacturing Market

  • 18.1. France Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Vaccine Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Vaccine Contract Manufacturing Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Vaccine Contract Manufacturing Market

  • 19.1. Italy Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Vaccine Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Vaccine Contract Manufacturing Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Vaccine Contract Manufacturing Market

  • 20.1. Spain Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Vaccine Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Vaccine Contract Manufacturing Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Vaccine Contract Manufacturing Market

  • 21.1. Eastern Europe Vaccine Contract Manufacturing Market Overview
  • 21.2. Eastern Europe Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Vaccine Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Vaccine Contract Manufacturing Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Vaccine Contract Manufacturing Market

  • 22.1. Russia Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Vaccine Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Vaccine Contract Manufacturing Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Vaccine Contract Manufacturing Market

  • 23.1. North America Vaccine Contract Manufacturing Market Overview
  • 23.2. North America Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Vaccine Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Vaccine Contract Manufacturing Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Vaccine Contract Manufacturing Market

  • 24.1. USA Vaccine Contract Manufacturing Market Overview
  • 24.2. USA Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Vaccine Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Vaccine Contract Manufacturing Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Vaccine Contract Manufacturing Market

  • 25.1. Canada Vaccine Contract Manufacturing Market Overview
  • 25.2. Canada Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Vaccine Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Vaccine Contract Manufacturing Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Vaccine Contract Manufacturing Market

  • 26.1. South America Vaccine Contract Manufacturing Market Overview
  • 26.2. South America Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Vaccine Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Vaccine Contract Manufacturing Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Vaccine Contract Manufacturing Market

  • 27.1. Brazil Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Vaccine Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Vaccine Contract Manufacturing Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Vaccine Contract Manufacturing Market

  • 28.1. Middle East Vaccine Contract Manufacturing Market Overview
  • 28.2. Middle East Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Vaccine Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Vaccine Contract Manufacturing Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Vaccine Contract Manufacturing Market

  • 29.1. Africa Vaccine Contract Manufacturing Market Overview
  • 29.2. Africa Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Vaccine Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Vaccine Contract Manufacturing Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Vaccine Contract Manufacturing Market Competitive Landscape And Company Profiles

  • 30.1. Vaccine Contract Manufacturing Market Competitive Landscape
  • 30.2. Vaccine Contract Manufacturing Market Company Profiles
    • 30.2.1. Pfizer Inc
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson & Johnson
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. AbbVie Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Sanofi
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. GlaxoSmithKline
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Vaccine Contract Manufacturing Market Other Major And Innovative Companies

  • 31.1. Merck KGaA
  • 31.2. Fujifilm Holdings Corporation
  • 31.3. Moderna
  • 31.4. BioNTech
  • 31.5. GSK Vaccines
  • 31.6. AstraZeneca PLC
  • 31.7. Ajinomoto Co. Inc.
  • 31.8. Icon plc
  • 31.9. Lonza Group AG
  • 31.10. Cytiva
  • 31.11. Catalent Inc.
  • 31.12. Charles River Laboratories International Inc.
  • 31.13. Serum Institute of India Pvt. Ltd
  • 31.14. Samsung Biologics
  • 31.15. WuXi Biologics

32. Global Vaccine Contract Manufacturing Market Competitive Benchmarking

33. Global Vaccine Contract Manufacturing Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Vaccine Contract Manufacturing Market

35. Vaccine Contract Manufacturing Market Future Outlook and Potential Analysis

  • 35.1 Vaccine Contract Manufacturing Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Vaccine Contract Manufacturing Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Vaccine Contract Manufacturing Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer